Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Chemotherapy and Its Effect on Liver Hypertrophy

  • Chapter
  • First Online:
Venous Embolization of the Liver

  • 1290 Accesses

Abstract

Systemic chemotherapy, which is routinely used before liver resection for colorectal liver metastases (CRLM), can induce parenchymal liver injury, including ­steatosis, steatohepatitis, and sinusoidal injuries leading to fibrosis. These chemo-induced lesions could decrease the tolerance of liver resection and impair liver regeneration resulting in a higher risk of postoperative complications. We aimed to review in this chapter the occurrence, rate, and consequences of preoperative chemotherapy in patients considered for liver resection of CRLM. We focused on the impact of chemotherapy on liver regeneration considering the need to pursuit oncological treatment in order to prevent tumoral development of CRLM in the future hypertrophied liver. The absence of hypertrophy after portal obstruction remains a contraindication to major liver resection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucoverin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.

    Article  PubMed  CAS  Google Scholar 

  2. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016.

    Article  PubMed  CAS  Google Scholar 

  3. Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94:274-286.

    Article  PubMed  CAS  Google Scholar 

  4. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460-466.

    Article  PubMed  CAS  Google Scholar 

  5. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845-853.

    Article  PubMed  Google Scholar 

  6. Sorensen P, Edal AL, Madsen EL, et al. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer. 1995;75:2592-2596.

    Article  PubMed  CAS  Google Scholar 

  7. Moertel CG, Fleming TR, Macdonald JS, et al. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol. 1993;11:2386-2390.

    PubMed  CAS  Google Scholar 

  8. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-2072.

    Article  PubMed  CAS  Google Scholar 

  9. Kleiner DE, Brunt ME, Natta MV, et al. Design and validation of a histological scoring system for nonalcoholoc fatty Liver disease. Hepatology. 2005;41:1313-1321.

    Article  PubMed  Google Scholar 

  10. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7:1034-1044.

    Article  PubMed  Google Scholar 

  11. Pathak S, Tang JM, Terlizzo M, et al. Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastases. Eur J Surg Oncol. 2010;36:52-57.

    Article  PubMed  CAS  Google Scholar 

  12. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761-2767.

    Article  PubMed  Google Scholar 

  13. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg. 2004;239:722-732.

    Article  PubMed  Google Scholar 

  14. Yamanaka N, Okamoto E, Kawamura E, et al. Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function. Hepatology. 1993;18:79-85.

    Article  PubMed  CAS  Google Scholar 

  15. Tani M, Tomiya T, Yamada S, et al. Regulating factors of liver regeneration after hepatectomy. Cancer Chemother Pharmacol. 1994;33(suppl):29-32.

    Article  Google Scholar 

  16. Ogasawara K, Une Y, Nakajima Y, et al. The significance of measuring liver volume using computed tomographic images before and after hepatectomy. Surg Today. 1995;25:43-48.

    Article  PubMed  CAS  Google Scholar 

  17. Tanaka W, Yamanaka N, Oriyama T, et al. Multivariate analysis of liver regenerative capacity after hepatectomy in humans. J Hepatobiliary Pancreat Surg. 1997;4:78-82.

    Article  Google Scholar 

  18. Shimada M, Matsumata T, Maeda T, et al. Hepatic regeneration following right lobectomy: estimation of regenerative capacity. Surg Today. 1994;24:44-48.

    Article  PubMed  CAS  Google Scholar 

  19. Fisher B, Szuch P, Levine M, et al. A portal blood factor as the humoral agent in liver regeneration. Science. 1971;171:575-577.

    Article  PubMed  CAS  Google Scholar 

  20. Starzl TE, Porter KA, Kashiwagi N, et al. Portal hepatotrophic factors, diabetes mellitus and acute liver atrophy, hypertrophy and regeneration. Surg Gynecol Obstet. 1975;141:843-858.

    PubMed  CAS  Google Scholar 

  21. Yao AH, Yang Y, Li XC, et al. Hepatic regenerative response in small-sized liver isografts in the rat. J Surg Res. 2010;161:328-335.

    Article  PubMed  Google Scholar 

  22. D’Angelica M, Martin RC, Jarnagin WR, et al. Major hepatectomy with simultaneous pancreatectomy for advanced hepatobiliary cancer. J Am Coll Surg. 2004;198:570-576.

    Article  PubMed  Google Scholar 

  23. Yokoyama Y, Nagino M, Nimura Y. Mechanism of impaired hepatic regeneration in cholestatic liver. J Hepatobiliary Pancreat Surg. 2007;14:159-166.

    Article  PubMed  Google Scholar 

  24. Lesurtel M, Graf R, Aleil B, et al. Platelet derived serotonin mediates liver regeneration. Science. 2006;312(5770):104-107.

    Article  PubMed  CAS  Google Scholar 

  25. Berhrns KE, Tsiotos GG, DeSouza NF, et al. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg. 1998;2:292-298.

    Article  Google Scholar 

  26. Parc Y, Dugué L, Farges O, Hiramatsu K, et al. Preoperative systemic 5-fluorouracil does not increase the risk of liver resection. Hepatogastroenterology. 2000;47(36):1703-1705.

    PubMed  CAS  Google Scholar 

  27. Yedibela S, Elad L, Wein A, et al. Neoadjuvant chemotherapy does not increase postoperative complication rate after resection of colorectal liver metastases. Eur J Surg Oncol. 2005;31:141-146.

    Article  PubMed  CAS  Google Scholar 

  28. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1-7.

    Article  PubMed  Google Scholar 

  29. Soubrane O, Brouquet A, Zalinski S, et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases. Ann Surg. 2010;251:454-460.

    Article  PubMed  Google Scholar 

  30. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118-124.

    Article  PubMed  Google Scholar 

  31. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983-4990.

    Article  PubMed  CAS  Google Scholar 

  32. Parikh AA, Gentner B, Wu TT, et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg. 2003;7:1082-1088.

    Article  PubMed  Google Scholar 

  33. Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11:860-868.

    Article  PubMed  Google Scholar 

  34. Hewes JC, Dighe S, Morris RW, et al. Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg. 2007;31:353-364.

    Article  PubMed  CAS  Google Scholar 

  35. Mehta NN, Ravikumar R, Coldham CA, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:782-786.

    Article  PubMed  CAS  Google Scholar 

  36. Nagasue N, Kobayashi M, Iwaki A, et al. Effect of 5-fluorouracil on liver regeneration and metabolism after partial hepatectomy in the rat. Cancer. 1978;41:435-443.

    Article  PubMed  CAS  Google Scholar 

  37. Di Stefano G, Derenzini M, Kratz F, et al. Liver-targeted doxorubicin: effects on rat regenerating hepatocytes. Liver Int. 2004;24:246-252.

    Article  PubMed  Google Scholar 

  38. Engum SA, Sidner RA, Miller GA, et al. Early use of cisplatin is safe after partial hepatectomy. J Pediatr Surg. 1993;28:411-417.

    Article  PubMed  CAS  Google Scholar 

  39. Beal IK, Anthony S, Papadopoulou A, et al. Portal vein embolization prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol. 2006;79:473-478.

    Article  PubMed  CAS  Google Scholar 

  40. Wicherts DA, de Haas RJ, Andreani P, et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg. 2010;97:240-250.

    Article  PubMed  CAS  Google Scholar 

  41. Goere D, Farges O, Leporrier J, et al. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg. 2006;10:365-370.

    Article  PubMed  Google Scholar 

  42. Covey AM, Brown KT, Jarnagin WR, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008;247:451-455.

    Article  PubMed  Google Scholar 

  43. Tanaka K, Kumamoto T, Matsuyama R, et al. Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases. J Gastrointest Surg. 2010;14:359-368.

    Article  PubMed  Google Scholar 

  44. Van Buren G, Yang A, Dallas N, et al. The effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol. 2008;26:1836-1842.

    Article  PubMed  Google Scholar 

  45. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008;26:5254-5260.

    Article  PubMed  Google Scholar 

  46. D’Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol. 2007;14:759-765.

    Article  PubMed  Google Scholar 

  47. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96-106.

    Article  PubMed  Google Scholar 

  48. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 2008;15:2765-2772.

    Article  PubMed  Google Scholar 

  49. Aussilhou B, Dokmak S, Faivre S, et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol. 2009;16:1553-1559.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Beaujon Hospital, Clichy, France

    Béatrice Aussilhou M.D.

  2. Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Beaujon Hospital, 100, boulevard du Général Leclerc, 92110, Clichy, France

    Jacques Belghiti

Authors
  1. Béatrice Aussilhou M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacques Belghiti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacques Belghiti .

Editor information

Editors and Affiliations

  1. New York-Presbyterian Hospital, New York, 10032, New York, USA

    David C. Madoff

  2. University of Tokyo, Hongo 7-3-1, Tokyo, 113-8656, Japan

    Masatoshi Makuuchi

  3. School of Medicine, Dept. Surgery I, Nagoya University, Tsurumai-cho 65, Nagoya, Aichi-ken, 466-8550, Japan

    Masato Nagino

  4. M.D. Anderson Cancer Center, Dept. Surgical Oncology, University of Texas, Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Jean-Nicolas Vauthey

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Aussilhou, B., Belghiti, J. (2011). Chemotherapy and Its Effect on Liver Hypertrophy. In: Madoff, D., Makuuchi, M., Nagino, M., Vauthey, JN. (eds) Venous Embolization of the Liver. Springer, London. https://doi.org/10.1007/978-1-84882-122-4_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-84882-122-4_27

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84882-121-7

  • Online ISBN: 978-1-84882-122-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation